OMA1520 and OMA1774, novel 1,2,4-triazole bearing analogs of combretastatin A-4, inhibit hepatocellular carcinoma: Histological and immunohistochemical studies - 16/04/21
, Ibrahim M. Shatla b, Dalia A. Abdelhafeez c, Muhamad Mustafa d, ⁎ , Omar M. Aly eBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 13 |
| Iconographies | 7 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Combretastatin A-4 (CA-4) received significant interest as a potential anticancer agent in recent years. Several CA-4 analogs were synthesized and investigated to enhance the activity or solve the in vivo decreased activity of CA-4.
Aim |
The present study aims to investigate the chemotherapeutic and the antiproliferative effects of the mono and the dual therapy of the newly synthesized CA-4 analogs OMA1520 and OMA1774 against hepatocellularcarcinoma (HCC) induced in male adult rats by N-methylnitrosourea (MNU).
Methods |
50 male rats were divided into 5 groups of 10 animals in each group. Group I: normal healthy control; group II: MNU treated group, group III: MNU animals treated by OMA1520, group IV: MNU animals treated by OMA1774, and group V: MNU animals treated by both OMA1520 and OMA1774. The rats were assessed for liver cancer progression or inhibition by evaluating the histopathological, immunohistochemical, biochemical, and antioxidant enzyme status.
Results |
The present work indicated that OMA1520 and OMA1774 possessed substantial chemotherapeutic efficiency against HCC. The histological and immunohistochemical examinations of liver tissues confirmed the biochemical sera data. Also, they diminished the cytotoxic effects of MNU and restored the normal histological hepatic architecture. Both analogs restored the normal levels of liver enzymes and functions and revealed potential antioxidant effects. OMA1520 and OMA1774 reduced the inflammatory and tumor markers' elevated expressions in serum.
Conclusion |
Substantial evidence in our results suggests that both CA-4 analogs could be possible alternative anticancer agents, and their co-administration provides a synergistic activity.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | New CA-4 analogs were tested against hepatocellular carcinoma induced in rats. |
• | The analogs reduced the number of HCC cells significantly. |
• | The analogs restored the normal levels of the liver enzymes. |
• | The analogs reduced the inflammatory and tumor markers expression. |
Keywords : Combretastatin A-4, Hepatocellular carcinoma, Anticancer drugs, Inflammatory cytokines, Tumor marker
Plan
Vol 138
Article 111417- juin 2021 Retour au numéro
Article précédent
- PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines
- Parisa Lotfinejad, Tohid Kazemi, Sahar Safaei, Mohammad Amini, Elmira Roshani asl, Elham Baghbani, Siamak Sandoghchian Shotorbani, Farhad Jadidi Niaragh, Afshin Derakhshani, Mahdi Abdoli Shadbad, Nicola Silvestris, Behzad Baradaran
- Plasmodium infection inhibits triple negative 4T1 breast cancer potentially through induction of CD8+ T cell-mediated antitumor responses in mice
- Jianhua Pan, Meng Ma, Li Qin, Zhongkui Kang, Dickson Adah, Zhu Tao, Xiaofen Li, Linglin Dai, Siting Zhao, Xiaoping Chen, Qin Zhou
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?